ArticleJournal of AIDS & clinical research2012
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.
Article in Journal of AIDS & clinical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A Systematic Literature Review of Mathematical Models for Coinfections: Tuberculosis, Malaria, and HIV/AIDS.Journal of multidisciplinary healthcare · 2024Review
- Paradox of COVID-19 in pregnancy: are pregnant women more protected against or at elevated risk of severe COVID-19?Future microbiology · 2022Review
- Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine.Molecular therapy oncolytics · 2022Article
- Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies.AIDS research and human retroviruses · 2018Review
- Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies.eLife · 2018Article
- An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.Clinical and vaccine immunology : CVI · 2017Article
- Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Current opinion in HIV and AIDS · 2017Review
- Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.Journal of virology · 2016Article
- Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.Science (New York, N.Y.) · 2016Article
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.International journal of molecular sciences · 2016Review
- Human Immunodeficiency Virus (HIV).Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Article
- Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.Journal of virology · 2016Article
- Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- The challenges of modelling antibody repertoire dynamics in HIV infection.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.The Journal of biological chemistry · 2015Article
- Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Current opinion in HIV and AIDS · 2014Review
- Article
- An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Frontiers in immunology · 2014Review
- Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.Vaccines · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the induction by active vaccination of antibodies that can potently neutralize a broad range of circulating virus strains is a goal not yet achieved, despite more than 2 decades of research. Here we review progress made in the field, from early empirical studies to today's rational structure-based vaccine antigen design. We discuss the existence of broadly neutralizing antibodies, their implications for epitope discovery and recent progress made in antigen design. Finally, we consider the relationship between antigenicity and immunogenicity for B cell recognition and antibody production, a major hurdle for rational vaccine design to overcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.